Q-omics provides the consensus-scored PYCR1 profile across patient tissues and cancer cell-line models. PYCR1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PYCR1 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, PYCR1 RNA expression shows 18,271 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, BLCA, and ACC as cancer lineages where PYCR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PYCR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PYCR1 survival associations across molecular data types. PYCR1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PYCR1 RNA expression–survival associations across cancer types. High PYCR1 expression shows unfavorable associations in KIRP, KIRC, ACC, LIHC, MESO and KICH. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PYCR1 RNA expression.
This table summarizes PYCR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PYCR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PYCR1 shows higher tumor expression in BLCA, KIRP, COAD, KIRC, LUAD and LIHC. The BLCA box plot shows higher PYCR1 RNA expression in tumor versus normal tissue (log2 FC = +2.896, t-test p < 0.001).
This table shows molecular features associated with PYCR1 in patient tissues and cancer cell lines. In patient samples, PYCR1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PYCR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
